Risk of deep venous thrombosis and pulmonary embolism in severe asthma

ISRCTN ISRCTN07043627
DOI https://doi.org/10.1186/ISRCTN07043627
Secondary identifying numbers Astmafonds 3.2.11.021
Submission date
09/11/2011
Registration date
30/11/2011
Last edited
29/10/2015
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Asthma is one of the most common long-term lung diseases. Most asthma can be controlled with inhaled corticosteroids and bronchodilators. Venous thromboembolism (VTE) is a serious, potentially fatal, condition where a blood clot forms in a vein. The aim of the study is to find out whether the risk of venous thromboembolism is increased in severe asthma and whether this is related to asthma severity and the use of corticosteroids.

Who can participate?
Patients aged over 18 with asthma.

What does the study involve?
The patients are asked to complete a questionnaire about their history of VTE, history of asthma and medication use. The results are then compared with a comparable reference general population. Because sex and age have a large influence on the incidence of VTE, the reference general population is matched by sex and age.

What are the possible benefits and risks of participating?
There are no known risks to participants.

Where is the study run from?
Academic Medical Centre, Amsterdam, The Netherlands
Medical Centre Leeuwarden, Leeuwarden, The Netherlands
Dutch high altitude Asthma Centre Davos, Switzerland
The study is coordinated by the Academic Medical Centre Amsterdam

When is the study starting and how long is it expected to run for?
December 2010 to May 2011

Who is funding the study?
Dutch Asthma Foundation

Who is the main contact?
Mr C.J. Majoor
c.j.majoor@amc.uva.nl

Contact information

Mr C Majoor
Scientific

Meibergdreef 9
Amsterdam
1105 AZ
Netherlands

Study information

Study designOpen label observational cross-sectional study
Primary study designObservational
Secondary study designCross sectional study
Study setting(s)Hospital
Study typeOther
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleRisk of deep venous thrombosis and pulmonary embolism in severe asthma: an observational study
Study objectives1. The prevalence of venous thromboembolism (VTE) is increased in patients with severe asthma as compared to the general population
2. The prevalence of VTE increases with severity of asthma
3. Use of corticosteroids is associated with increased prevalence of VTE in patients with asthma
Ethics approval(s)The questionnaire was qualified as no overburden for the patient. Therefore no Medical Ethics Committee approval was needed.
Health condition(s) or problem(s) studiedAsthma
InterventionAll patients will complete a questionnaire about:
1. History of deep venous thrombosis (DVT) and pulmonary embolism (PE)
2. History of asthma
3. Medication use
The results of all included patients will be compared with a comparable reference general population (Naess IA, et al. J Thromb Haemost 2007 April;5(4):692-9). Because sex and age have a large influence on the incidence of DVT and pulmonary embolism (PE), the reference general population will be matched to sex and age for all patients. The study population will be compared with the reference general population by indirect standardisation.
Intervention typeOther
Primary outcome measureCumulative number of first DVT and PE events during lifetime as compared to the sum of the expected cumulative hazards of first DVT and PE events from all patients in an age- and sex-matched general population
Secondary outcome measuresHazard ratio for PE and DVT of of asthma associated factors (like oral and inhalational corticosteroids, atopy, duration of asthma, age of onset)
Overall study start date01/12/2010
Completion date01/05/2011

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
Upper age limit88 Years
SexBoth
Target number of participants550 (275 mild/moderate asthma and 275 severe asthma patients)
Key inclusion criteria1. Age 18-88 years old
2. Patients recruited from outpatient clinics from the Academic Medical Centre Amsterdam, Medical Center Leeuwarden and the Dutch High Altitude Asthma Clinic, Davos, Switzerland
3. Confirmed diagnosis of asthma according to Global Initiative for Asthma (GINA) 2010 guidelines
4. Diagnosis of severe asthma according to the international consensus 2009 (IMI-UBIOPRED)
Key exclusion criteria1. Severe co-morbidities that could interfere with coagulation (Including cancer, other severe inflammatory diseases and human immunodeficiency virus (HIV)
2. Severe psychiatric illness
Date of first enrolment01/12/2010
Date of final enrolment01/05/2011

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Meibergdreef 9
Amsterdam
1105 AZ
Netherlands

Sponsor information

Astmafonds (Netherlands)
Research organisation

Postbus 627
Amersfoort
3800 AP
Netherlands

Website http://www.astmafonds.nl/
ROR logo "ROR" https://ror.org/00ddgbf74

Funders

Funder type

Research organisation

Astmafonds (Netherlands) (ref: 3.2.11.021)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan